Canaccord reiterates Hims & Hers stock rating on peptide launch
Canaccord Genuity has maintained its positive outlook on Hims & Hers Health stock, reaffirming a Buy rating and setting a price target of $40.00 for the company's shares. The decision comes after the healthcare firm launched Peptides+, a new line of peptide treatments that includes five US-compounded injectables such as Sermorelin, NAD+, glutathione, vitamin B12, and L-carnitine. The company plans to expand its peptide offerings with BPC-157 and TB-500 once the regulatory landscape allows.
Pricing for the peptide treatments ranges from roughly $150 to $200 per month, which also includes a mandatory Care+ membership providing lab and provider support. Hims & Hers has reported robust growth over the past year, with nearly 30% revenue growth and a gross margin of 64.81%. Analysts project profitability for the company this year, making it one of the exclusive insights available to subscribers.
Canaccord Genuity expects the peptide treatments to contribute significantly to revenue as the product portfolio continues to grow. The company is also manufacturing its own active pharmaceutical ingredients for BPC-157 and TB-500 at its California facility, as well as implementing a verticalized supply chain for its products.
Despite these positive developments, Hims & Hers faced a 49% year-over-year revenue increase, which was within its guidance of $880 million to $900 million. However, the company experienced a decline in subscribers, with a 100,000-person reduction in the third quarter attributed to reduced marketing efforts in the U.S. weight-loss segment. This decline led other analysts, such as JPMorgan and Needham, to lower their price targets on the stock.
On a positive note, international revenue has grown more than fourfold year-over-year, highlighting the company's strategic investments in international expansion. KeyBanc has maintained a Sector Weight rating and noted 2026 as a critical transition year for the firm, as it focuses on AI development, new treatments, and international growth.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.